Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Waldenström Macroglobulinemia, An Issue of Hematology/Oncology Clinics of North America E-Book
This issue of Hematology/Oncology Clinics, edited by Drs. Jorge J. Castillo, Efstathios Kastritis, and Steven P. Treon, will focus on Waldenström Macroglobulinemia. Topics include, but are not limited to, Genomics; Epigenomics; Flow cytometry; Marrow microenvironment; Familial Waldenstrom; MYD88 L265P and other MYD88 mutations; CXCR4 and other recurrent mutations; Diagnosis and differential diagnosis; Criteria to treat and treatment goals; Alkylators; Monoclonal antibodies; Proteasome inhibitors; BTK inhibitors; Transplant; and Novel approaches.
Immunotherapy in Cancer, An Issue of Hematology/Oncology Clinics of North America
This issue of Hematology/Oncology Clinics, guest edited by Patrick A. Ott, will focus on Immunotherapy in Cancer. Topics include, but are not limited to, Cancer Vaccines, Innate Immune stimulation, Costimulatory and Agonistic Antibodies, Immune modulation with radiation, Oncolytic virus therapy, Cytokine Therapy, Adoptive T cell transfer, Immune related toxicity, and Immune checkpoint combinations.
Myeloma
Myeloma is the second-most common hematologic cancer, accounting for approximately 1 percent of all cancers and 2 percent of all deaths from cancer. In recent years there have been major and significant advances in the diagnosis, imaging, molecular pathogenesis, and therapy of myeloma. This book describes these advances in a single, practical volume, placing them in the context of daily clinical practice. Different myeloma subtypes are discussed in individual chapters, integrating etiology, pathogenesis, molecular pathology, histology, and therapy in a single place for each condition. The book begins by discussing epidemiology, imaging techniques, pathogenesis, and other general considerations. Conditions covered in detail include multiple myeloma, POEMS syndrome, Castleman's syndrome, Waldenstrom's macroglobulinemia, amyloidosis and MGUS. Featuring color illustrations, and written and edited by leading authorities in the field, Myeloma provides readers with the information they need to diagnose and manage these complex disorders.
Oxford Textbook of Clinical Nephrology
Illustrated in full colour throughout, this comprehensive edition provides the reader with complete information on clinical and practical problems in nephrology.
Neoplastic Diseases of the Blood
Neoplastic Diseases of the Blood integrates the history, epidemiology, pathology, pathophysiology, and therapeutics of modern neoplastic hematopathology. The book is divided into five major sections, with the first four covering the spectrum of hematologic neoplasia— Chronic Leukemias and Related Disorders , Acute Leukemias, Myeloma and Related Disorders, and Lymphomas. The fifth section covers a variety of topics in supportive care. Now in its fifth edition, this classic and invaluable text brings together a team of internationally renowned experts and offers in-depth coverage of the complex interface between diagnosis and therapy. Chapters feature an accessible and easy-to-read layout and provide updates on the tremendous progress made in the last decade in the understanding of the nature of hematologic malignancies and their treatment. An authoritative and indispensable resource for students, trainees, and clinicians, this fifth edition is sure to distinguish itself as the definitive reference on this topic.
HCV Infection and Cryoglobulinemia
The first observation of cold-induced precipitation of serum proteins dates back to 1933, when Wintrobe and Buell first described an unusual case of multiple myeloma in a woman whose serum reversibly precipitated at cold temperatures. In 1947 Lerner and Watson showed cold-precipitable proteins to be gammaglobulins and called them ‘cryoglobulins’ and the corresponding clinical condition ‘cryoglobulinemia’. Meltzer and Franklin in 1966 provided an accurate description of the typical clinical symptoms associated with cryoglobulinemia, showed that they consisted of two different globulin components and, because of the ignorance on its etiology, called this clinical condition ‘essential...
Novel Agents for Multiple Myeloma
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. It accounts for approximately 1.8% of all hematologic and solid cancers and slightly > 15% of hematologic malignancies in the United States. MM is typically sensitive to different classes of cytotoxic drugs, both as frontline treatment and as treatment for relapsed disease. Unfortunately, even if responses are typically durable, nowadays MM is not considered curable with current approaches. However, MM survival rates have been brilliantly improved thanks to the introduction of novel agents: patients diagnosed after 2010 have had higher rates of novel therapy use and better survival outcomes compared with those of earlier years. Most relevant therapeutic advances over the past decades has been the introduction of novel therapies, such as immune-modifying agents (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib), adopted with or without stem cell transplantation.
Waldenström Macroglobulinemia, An Issue of Hematology/Oncology Clinics of North America, E-Book
In this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of Waldenström Macroglobulinemia. Top experts in the field provide a focused update on the biology, diagnosis and management, and novel therapies for patients with Waldenström macroglobulinemia, a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow. Contains 14 practice-oriented topics including clinical implications of genomic profile in Waldenström macroglobulinemia; chemoimmunotherapy regimens in the frontline management of Waldenström macroglobulinemia; management of rela...
Waldenström’s Macroglobulinemia
This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease. Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenström first reported this “new syndrome“ 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.
